Tirzepatide Excites in Obesity Now Too, Says Lilly

The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon for type 2 diabetes.
Medscape Medical News

source https://www.medscape.com/viewarticle/972936?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?